Adamantinoma

View larger

Adamantinoma is a rare low-grade malignant bone tumour with distinctive biphasic histology featuring epithelial cells within an osteofibrous stroma. It has a remarkable predilection for the tibial diaphysis and represents less than 0.5% of all primary bone tumours.

Key epidemiological features:

• Incidence: Accounts for less than 1% of primary malignant bone tumours
• Age distribution: Peak between 20-50 years (range 2-86 years)
• Gender: Slight male predominance (5:4 ratio)
• Location: 80-85% occur in the tibial diaphysis

Risk factors:

• No established genetic predisposition identified
• Possible association with osteofibrous dysplasia (OFD)
• History of prior trauma reported in 60% of patients (uncertain significance)
• No association with radiation or chemical exposure

View larger

Histological Features

Adamantinoma is characterised by its distinctive biphasic histology with epithelial and osteofibrous components that may be intermingled in various proportions.

Epithelial Component:

• Nests, cords, or tubules of epithelial cells
• Positive for cytokeratins 14, 19 (but negative for CK8, CK18)
• Four histological patterns: basaloid, tubular, spindle-cell, squamous
• Peripheral palisading of cells may be seen

View larger

Osteofibrous Component:

• Fibrous stroma with woven bone trabeculae
• Similar to osteofibrous dysplasia
• Contains scattered osteoclast-like giant cells
• Positive for vimentin

Relationship to Osteofibrous Dysplasia

A controversial but clinically important relationship exists between adamantinoma and osteofibrous dysplasia (OFD):

Proposed pathogenic relationship (a genuine controversy):

• The Leiden group demonstrated keratin-positive epithelial cells emerging individually from the osteofibrous stroma, with progressively organised basement membrane around cohesive epithelial islands - evidence that OFD-like adamantinoma may be a precursor to classic adamantinoma via fibrous-to-epithelial transformation (Hazelbag, Hum Pathol 1997).
• The Mayo Clinic counterargument: in 80 OFD cases followed for up to 31 years, no lesion progressed to adamantinoma and two matured into fibrous dysplasia, suggesting OFD is a variant of fibrous dysplasia rather than an obligate precursor (Park & Unni, Hum Pathol 1993).
• Reconciled view: OFD, differentiated (OFD-like) adamantinoma and classic adamantinoma form a histological continuum, but pure OFD does not inevitably become malignant - hence cytokeratin immunohistochemistry is essential to detect the epithelial component.

Molecular Features

• Aneuploidy is confined to the epithelial cells. DNA cytometry shows aneuploid nuclei only in cells of epithelial phenotype, while the fibrous cells remain diploid - direct evidence that the malignant clone is epithelial and the osteofibrous tissue is reactive (Hazelbag, Am J Pathol 1995).
• p53 abnormalities (immunoreactivity and loss of heterozygosity at the p53 locus) are detectable in roughly half of tumours and again localise to the epithelial component (Hazelbag, Am J Pathol 1995).
• No specific recurrent fusion gene has been identified (unlike the EWSR1 rearrangement of Ewing sarcoma), which is a useful diagnostic discriminator.
• GNAS mutations characteristic of fibrous dysplasia are not a feature, helping separate adamantinoma/OFD from fibrous dysplasia.
• Lung metastases contain only keratin-positive epithelial cells, with no osteofibrous element, confirming the epithelial cells as the metastasising population (Hazelbag, Am J Pathol 1995).

View larger

Tumour-Related Complications

Surgical Complications

Managing Recurrence

Local recurrence is the most significant complication. Assessment includes:

1. Imaging: MRI of local site, CT chest, bone scan/PET
2. Biopsy: Confirm recurrence histologically
3. Surgical planning: Review margins from primary surgery

Treatment Options:

• Wide re-excision if margins achievable
• Amputation if limb salvage not possible
• Palliative care for unresectable/metastatic disease

View larger

Immediate Postoperative Care

Day 0-3:

• DVT prophylaxis (mechanical and pharmacological)
• Drain management - remove when output under 50ml per 24 hours
• Pain management - PCA then oral analgesia
• Non-weight bearing on affected limb

Week 1-6:

• Wound surveillance - watch for infection
• Protected weight bearing (depends on reconstruction)
• Physiotherapy for ROM and muscle strengthening
• Monitor for DVT/PE

Rehabilitation Protocol

Reconstruction-Specific Considerations:

• Allograft: Non-weight bearing 6-12 weeks until union
• Vascularised fibula: Progressive weight bearing as fibula hypertrophies
• Endoprosthesis: Earlier weight bearing (2-4 weeks)

Return to Activity

• Desk work: 4-6 weeks (depends on pain control)
• Manual work: 3-6 months
• Sports: Generally low-impact activities recommended
• Driving: When off opioids and can weight bear for emergency stop

View larger

Global Epidemiology

Adamantinoma accounts for well under 1% of all primary bone tumours, making it one of the rarest malignant bone neoplasms encountered worldwide. The disease is remarkably consistent across populations: the tibia is the dominant site (around 70-85% of cases), the peak incidence is in the second to fifth decades, and there is no described geographic, ethnic or environmental predisposition. The tumour has not been linked to radiation or to a hereditary cancer syndrome. Because the absolute numbers are so small, no national cancer registry generates adamantinoma-specific incidence figures of high precision, and the evidence base is built almost entirely from single-institution and tertiary-referral case series rather than trials.

Side-by-Side Guideline and Society Guidance

There is no disease-specific randomised evidence; all major bodies converge on the same principles, derived from retrospective series (evidence level IV) and expert consensus. Differences are largely organisational rather than oncological.

Registry and Centralisation Evidence

Because adamantinoma is so uncommon, the strongest registry-level lesson is centralisation: outcomes for primary bone tumours improve when biopsy and surgery are performed at high-volume sarcoma units, and a poorly planned biopsy outside such a unit can compromise limb salvage. National and supranational sarcoma networks (for example the European EURACAN reference network and equivalent national bone tumour services) exist precisely to pool these rare cases. There is no arthroplasty-style implant registry relevant to adamantinoma, but limb-salvage reconstruction outcomes (allograft, vascularised fibula, endoprosthesis) are tracked within institutional and bone tumour databases.

Practice Variation

The principal real-world variation is in reconstruction technique and resource availability rather than oncological strategy. Wide resection is universal, but the choice between intercalary allograft, vascularised fibular autograft, allograft-prosthesis composite and endoprosthesis depends on resection length, patient age and - importantly in lower-resource settings - access to bone banks and custom implants. Where advanced prostheses and allografts are unavailable, free vascularised fibular grafting is a well-described and effective alternative (Farooque, J Orthop Case Rep 2024). Across all systems, lifelong surveillance for late local recurrence and pulmonary metastasis is the shared standard, reflecting documented recurrences decades after index surgery.